Measuring blood flow during liver embolization procedures
qDSA Blood Flow Measurement in Patients Undergoing Transarterial Embolization (TAE) of the Liver
This study is testing a new method to measure blood flow in patients getting liver embolization to see if it helps make treatments for liver tumors more effective.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT06971991 on ClinicalTrials.gov |
What this trial studies
This research evaluates a new technique called quantitative digital subtraction angiography (qDSA) to measure blood flow in patients undergoing liver embolization procedures. The goal is to ensure that the blood flow to liver tumors is effectively reduced by calculating blood flow before, during, and after the embolization. Up to 20 participants will be enrolled for a single study visit, with data collection extending for up to six months. This innovative approach aims to enhance the precision of liver cancer treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are patients scheduled for transarterial embolization of liver tumors who can provide informed consent.
Not a fit: Patients who are pregnant, breastfeeding, or have severe kidney issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this technique could improve the effectiveness of liver cancer treatments by ensuring optimal blood flow reduction to tumors.
How similar studies have performed: While this approach is innovative, similar studies using advanced imaging techniques have shown promise in improving treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule Exclusion Criteria: * Pregnancy or breastfeeding * Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function. * Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure. * Patients with a physical or psychological condition that would impair study participation. * The patient is judged unsuitable for study participation by the Investigator for any other reason
Where this trial is running
Madison, Wisconsin
- UW Hospital and Clinics — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Paul Laeseke, MD, PhD — UW School of Medicine and Public Health
- Study coordinator: Radiology Coordinators
- Email: Radstudy@uwhealth.org
- Phone: 608-282-8349
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.